Related Experiment Video
Updated: Jul 18, 2026
10:29
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance
Grant Nash Colfax1, Eric Vittinghoff, Robert Grant
1AIDS Office, San Francisco Department of Public Health, San Francisco, California, USA.
AIDS (London, England)
|January 2, 2007
Summary
Frequent methamphetamine use is linked to higher rates of primary HIV drug resistance, specifically non-nucleoside reverse transcriptase inhibitor resistance, in men who have sex with men. This may stem from treatment interruptions in HIV source partners.
Area of Science:
- Infectious Diseases
- Virology
- Public Health
Background:
- HIV drug resistance poses a significant challenge to effective treatment and prevention strategies.
- Understanding risk factors for primary HIV drug resistance is crucial for public health interventions.
- Methamphetamine use is prevalent in certain populations and may influence HIV transmission and resistance patterns.
Purpose of the Study:
- To investigate the association between methamphetamine use and the prevalence of primary HIV drug resistance.
- To identify specific classes of antiretroviral drugs for which resistance is associated with methamphetamine use.
- To explore potential mechanisms linking methamphetamine use to HIV drug resistance.
Main Methods:
- A cohort study of men who have sex with men recently infected with HIV was analyzed.
- Multivariate statistical analysis was employed to assess associations.
- Prevalence of primary drug resistance to different antiretroviral drug classes was determined.
Main Results:
- Frequent methamphetamine use was significantly associated with primary non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance.
- No significant association was found between methamphetamine use and primary protease inhibitor (PI) or nucleoside reverse transcriptase inhibitor (NRTI) resistance.
- The findings suggest a specific link between methamphetamine use and resistance to NNRTIs.
Conclusions:
- Methamphetamine use is a potential risk factor for primary NNRTI resistance in recently HIV-infected men who have sex with men.
- The observed association may be mediated by methamphetamine-associated treatment interruptions in HIV source partners.
- Further research is warranted to elucidate the complex interplay between substance use, HIV treatment adherence, and drug resistance.
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
00:36Viral Mutations
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material for adaptive...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...